1.Ahn, S H, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatology International 2010; 4: 386–395.
2.Plymoth, A, Viviani, S, Hainaut, P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Letters 2009; 286: 15–21.
3.Fung, J, Lai, CL, Yuen, MF. Hepatitis B and C virus-related carcinogenesis. Clinical Microbiology and Infection 2009; 15: 964–970.
4.Kao, JH, et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. Journal of Pediatrics 2001; 139: 349–352.
5.Montesano, R. Hepatitis B immunization and hepatocellular carcinoma; The Gambia Hepatitis Intervention Study. Journal of Medical Virology 2002; 67: 444–446.
6.Chang, MH, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20 year follow-up. Journal of the National Cancer Institute 2009; 101: 1348–1355.
7.Brook, MG, et al. Antenatal screening for hepatitis B is medically and economically effective in the prevention and vertical transmission: three years experience in a London. Quarterly Journal of Medicine 1989; 71: 313–317.
8.Dwyer, MJ, McIntyre, PG. Antenatal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area. Epidemiology and Infection 1996; 117: 121–131.
9.Jordan, R, Law, M. An appraisal of the efficacy and cost effectiveness of antenatal screening for hepatitis B. Journal of Medical Screening 1997; 4: 117–127.
10.Balogun, MA, et al. Acute hepatitis B infection in England and Wales: 1985–1996. Epidemiology and Infection 1999; 122: 125–133.
11.Hahné, S. et al. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy. Journal of Clinical Virology 2004; 29: 211–220.
12.Hurie, MB, Mast, EE, Davis, JP. Horizontal transmission of hepatitis B infection to United States born children of Hmong refugees. Pediatrics 1992; 89: 269–273.
13.Diel, R, Helle, J, Gottschalk, R. Transmission of hepatitis B in Hamburg, Germany, 1998–2002 a perspective population based study. Medical Microbiology and Immunology 2005; 194: 193–199.
14.Davis, LG, Weber, DJ, Lemon, SM. Horizontal transmission of hepatitis B virus. Lancet 1989; 1: 889–893.
15.Martinson, FE, et al. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. American Journal of Epidemiology 1998; 147: 478–487.
16.Doganci, T, et al. Horizontal transmission of hepatitis B virus in children with chronic hepatitis B. The World Journal of Gastroenterology 2005; 11: 418–420.
17.Hahné, S, et al. Hepatitis B incidence among South Asian children in England and Wales: implications for immunisation policy. Archives of Disease in Childhood 2003; 88: 1082–1083.
18.Değertekin, H, Tuzcu, A, Yalçin, K. Horizontal transmission of HBV infection among students in Turkey. Public Health 2000; 114: 411–412.
19.Mckie, A, Vyse, A, Maple, C. Novel methods for the detection of microbial antibodies in oral fluid. Lancet Infectious Diseases 2002; 2: 18–24.
20.Vyse, AJ, Cohen, BJ, Ramsay, ME. A comparison of oral fluid collection devices for use in the surveillance of virus diseases in children. Public Health 2001; 115: 201–207.
21.Chatzipantazi, P, et al. The feasibility and acceptability of collecting oral fluid from healthy children for anti-HCV testing. Archives of Disease in Childhood 2004; 89: 185–187.
22.Parry, JV, et al. Diagnosis of hepatitis A and B by testing saliva. Journal of Medical Virology 1989; 28: 255–260.
23.Parry, J. Simple and reliable salivary tests for HIV and hepatitis A and B virus diagnosis and surveillance. Annals of the New York Academy of Sciences 1993; 694: 216–233.
24.Thornton, L, et al. Comparison between self-reported hepatitis B, hepatitis C, and HIV antibody status and oral fluid assay results in Irish prisoners. Communicable Disease and Public Health 2000; 3: 253–255.
25.Parry, JV, Perry, KR, Mortimer, PP. Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. Lancet 1987; 2: 72–75.
26.Yusof, JH, Flower, AJ, Teo, CG. Transmission of hepatitis B virus analyzed by conformation-dependent polymorphisms of single-stranded viral DNA. Journal of Infectious Diseases 1994; 169: 62–67.
27.Hesketh, LM, et al. Childhood infection with hepatitis A and B viruses in England and Wales. Communicable Disease Report 1997; 7: R60–R63.
28.Franks, AL, et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. New England Journal of Medicine 1989; 321: 1301–1305.
29.Mahoney, FJ, et al. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics 1995; 96: 1113–1116.
30.Yao, GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996; 38: S39–S42.
31.Hsu, SC, et al. Horizontal transmission of hepatitis B virus in children. Journal of Pediatric Gastroenterology and Nutrition 1993; 16: 66–69.
32.Martinson, FE, et al. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. American Journal of Epidemiology 1998; 147: 478–487.
33.Kawsar, M, Goh, BT. Hepatitis B virus infection among Chinese residents in the United Kingdom. Sexually Transmitted Infections 2002; 78: 166–168.
34.Aweis, D, et al. Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpool. Communicable Disease and Public Health 2001; 4: 247–252.
35.Gjørup, IE, et al. Changing epidemiology of HBV infection in Danish children. Journal of Infection 2003; 47: 231–235.
36.Fisker, N, et al. Low hepatitis B prevalence among pre-school children in Denmark: saliva anti-HBc screening in day care centres. Journal of Medical Virology 2002; 68: 500–504.
37.Burgess, MA, et al. Hepatitis B in urban Australian schoolchildren. No evidence of horizontal transmission between high-risk and low risk groups. Medical Journal of Australia 1993; 159: 315–319.
38.Repp, R, et al. Risk of hepatitis B transmission in school. Lancet 1994; 344: 961–962.
39.Hayashi, J, et al. Hepatitis B virus transmission in nursery schools. American Journal of Epidemiology 1987; 125: 492–498.
40.Goldstein, ST, et al. Incidence and risk factors for acute heparitis B in the United States 1982–1998 implications for vaccination program. Journal of Infectious Diseases 2002; 185: 713–719.
41.Ramsay, M, et al. Control of hepatitis B in the United Kingdom. Vaccine 1998; 16 (Suppl.) S52–S55.
42.Lindh, M, et al. Hepatitis B carriers in Sweden: effects of immigration. Scandinavian Journal of Infectious Diseases 1993; 25: 411–416.
43.Veldhuijzen, IK, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection Is cost-effective. Gastroenterology 2010; 138: 522–530.
44.Tilson, L, et al. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. European Journal of Public Health 2007; 18: 275–282.
45.Edmunds, WJ. Universal or selective immunisation againsthepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Communicable Disease and Public Health 1998; 1: 221–228.
46.Etuwewe, O, Wood, A, Lyon, A. Delivering a selective neonatal BCG vaccination programme in a multi-ethnic community: an audit of the neonatal BCG immunisation programme in Birmingham and Solihull. Communicable Disease and Public Health 2004; 7: 172–176.
47.Galama, JM. National hepatitis B vaccination closer to implementation but not soon enough: recommendation s from the Dutch Health Council. Nederlands Tijdschrift voor Geneeskunde 2001; 145: 1339–1342.
48.Gay, NJ, Edmunds, WJ. Developed countries could pay for hepatitis B vaccination in developing countries. British Medical Journal 1998; 316: 1457.
49.Larcher, VF, et al. Overcoming barriers to hepatitis B immunisation by a dedicated hepatitis B immunisation service. Archives of Disease in Childhood 2001; 84: 114–119.
50.Giraudon, I, et al. Factors associated with incomplete vaccination of babies at risk of perinatal hepatitis B transmission: a London study in 2006. Vaccine 2009; 27: 2016–2022.